Clinical Trial

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

Withdrawn Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
This study-level decision was based on the evolving treatment landscape and strategic portfolio considerations and is not related to any safety concern.
Summary
The study will test the efficacy and safety of petosemtamab in combination with Pembrolizumab in first line patients with squamous non-small cell lung cancer and non-squamous non-small cell lung cancer.
Protocol Amendment History 4 changes
critical Trial status changed: Recruiting → Withdrawn 2026-07-03
notable Enrollment reduced: 180 -> 0 participants 2026-07-03
notable Trial sites expanded: 17 -> 24 locations 2026-06-06
notable Trial sites expanded: 5 -> 17 locations 2026-05-27
Trial Details
NCT Number NCT07353957
Lead Sponsor Merus B.V.
Conditions Lung Cancer - Non Small Cell Squamous, Lung Cancer - Non Small Cell Non-Squamous
Start Date 2026-03-27
Primary Completion 2028-05-31 (estimated)
Study Completion 2031-02-27 (estimated)
Updated on ClinicalTrials.gov 2026-08-13